NextPoint Therapeutics, Inc.

About

NextPoint Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts. The company specializes in precision immuno-oncology and tumor-directed therapeutics, specifically targeting the B7-H7/HHLA2 immune checkpoint axis to treat cancers that do not respond to PD-1/L1 inhibitors. Founded by scientists who discovered the HHLA2 pathway, NextPoint has initiated first-in-class clinical trials aimed at this innovative approach. The company’s pipeline includes several promising therapies, such as NPX372, a T-cell engager designed for enhanced efficacy and safety; NPX125, an antibody-drug conjugate for targeted tumor killing; and NPX887, a multi-functional checkpoint inhibitor that aims to restore T-cell activation. NextPoint is committed to advancing its research through a biomarker-driven strategy, focusing on cancers with B7-H7 upregulation. With a dedicated team of experienced drug developers, NextPoint is actively expanding its efforts in immuno-oncology.